Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
Article
[키워드] acute respiratory syndrome
amino acid substitution
amubarvimab (BRII-196)
antibody
antibody cocktail
Clinical efficacy
Combination
controls
coronavirus
coronavirus disease
COVID-19
demonstrated
Emergency use authorization
epitope
EUA
Evolution
half-maximal inhibitory concentration
half-maximal inhibitory concentration (IC50)
in vitro
introduced
less
Lung pathology
Lungs
M252Y/S254T/T256E (YTE)
mAb
mAbs
Modification
monoclonal antibody
monoclonal antibody (mAb)
Mutation
neutralize
neutralized
Neutralizing
Post-infection
Preclinical
RBD
receiving
Receptor binding domain
receptor binding domain (RBD)
reduce
reduced
regions
regulatory authority
resulting
retained
romlusevimab (BRII-198)
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 variants
serum
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
significantly
Spike protein
Support
susceptibility
therapeutic option
variant
Variant of concern (VOC).
variants
variants of concern
Viral load
virus
virus
VoC
weight loss
[DOI] 10.3389/fimmu.2022.980435 PMC 바로가기
[DOI] 10.3389/fimmu.2022.980435 PMC 바로가기